Combining an antibody-drug conjugate with the PARP inhibitor olaparib overwhelmed non-small cell lung cancer’s DNA-repair defenses — and roused the immune system — in preclinical models.
The structured financing releases cash as seralutinib hits regulatory milestones, funding the biotech through a planned NDA submission for pulmonary hypertension.
The agency’s digital health leader says clarity is on the way — both broad guidance on generative AI and more specialized guidance for higher-risk uses.
Male sex hormones dampened allergic lung inflammation in mice by strengthening nerve signals — a mechanism that may help explain why boys often outgrow asthma more than girls.
Expressable becomes the first speech-therapy provider on Amazon’s Health Benefits Connector, which matches shoppers to digital-health services their employer plans already cover.
The Korean biotech will tap Eli Lilly’s labs, scientists and infrastructure to speed its RNA-based gene therapies — an incubator arrangement, not an acquisition.
Licensing HM17321 from Korea’s Hanmi, Roche is chasing the next frontier in weight loss: shedding fat while preserving the muscle that today’s GLP-1 drugs also strip away.
The agency paused testing of RGX-121 after spinal MRI abnormalities turned up in patients treated years ago — the second clinical hold on a Regenxbio program in 2026.
The European Commission approved teclistamab plus daratumumab for relapsed multiple myeloma after a trial cut the risk of progression or death by more than 80%.
Analyzing thousands of people, researchers found that drugs from antibiotics to antidepressants left fingerprints in the gut — some detectable years after the last dose.
The renewed alliance keeps subspecialty expertise, tumor conferences and clinical-trial access available to patients closer to home, with new local cancer services coming this autumn.
A new analysis of grocery data suggests banning soda from food-assistance benefits cut soda buying — but shoppers redirected much of the money to other sugary drinks.